Our experts agree that there are many simple ways to minimize the chances of breast cancer returning. Adopting a healthy ...

The results of a clinical trial published last month targeted breast cancer "sleeper cells," which are cells that break away ...

ST. LOUIS – A groundbreaking treatment has been announced for women with an extremely aggressive form of breast cancer. Siteman Cancer Center just released the results of a clinical trial showing a ...

The team, led by oncologist Dr. Angela DeMichele, has advanced a method to identify and attack these dormant cells. Called ...

Patients with advanced triple negative breast cancer ineligible for immunotherapy may overcome their typically poor prognosis ...

Triple Negative Breast Cancer (TNBC) is one of the most aggresive types of breast cancer. It’s the kind of breast cancer that doesn’t have estrogen receptors, progesterone receptors, and human ...

A small clinical trial conducted at WashU Medicine shows promising results for patients with triple-negative breast cancer who received an investigational vaccine designed to prevent recurrence of ...

From left to right, Dr. Fernando Lecanda, Dr. Karmele Valencia, and Dr. Rafael Martínez Monge, from the Adhesion and Metastasis group at Cima, with Dr. Borja Ruiz-Fernández de Córdoba, also author of ...

Atezolizumab addition to chemotherapy post-surgery showed no significant improvement in invasive disease-free survival for high-risk TNBC patients. The study reported a higher incidence of severe ...

A newly developed antibody which restricts the growth of treatment-resistant breast cancers offers new hope for patients. It ...

Tecentriq with chemotherapy did not significantly improve EFS in TNBC patients, with a four-year EFS rate of 85.2% versus 81.9% for placebo. No overall survival benefit was observed with Tecentriq, ...